AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push

Enveda raises $311M for late-stage obesity and inflammatory disease treatments, paving the way for a potential IPO.

Biotech company Enveda has raised $311 million in funding for its late-stage obesity and inflammatory disease treatments.

Enveda has raised a total of $845 million in the past six years.

The latest funding round is intended to pave the way for an initial public offering (IPO) someday.